Core Viewpoint - Autonomix Medical, Inc. has received a new patent that enhances its catheter-based technology, indicating significant potential for application and expansion in treating diseases related to the nervous system [1][2]. Patent and Technology Development - The European Patent Office has granted Patent No. 3,226,792, which covers methods and systems for regulating organ and tumor growth, particularly in the field of neuromodulation [1]. - The company has a growing global patent portfolio with over 80 issued patents and 40 pending applications, showcasing its commitment to innovation [1][2]. Applications and Market Potential - The '792 patent includes methods to sense, ablate, and verify neurological traffic related to the prostate and lower urinary tract, potentially addressing conditions such as chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction [3]. - The technology aims to target pain associated with pancreatic cancer by focusing on the celiac plexus, with plans to expand its applications to various peripheral nerve bundles [2][6]. Clinical Trials and Future Plans - The company is preparing to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 for the Autonomix Sensing and RF Ablation System, aimed at treating pancreatic cancer pain [4]. - The technology is positioned as a platform that could address multiple indications across a wide disease spectrum, including cardiology and chronic pain management [6]. Company Overview - Autonomix Medical, Inc. is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, utilizing a catheter-based microchip sensing array for enhanced neural signal detection [5].

Core Viewpoint - CVRx, Inc. anticipates first quarter 2025 revenue of approximately $12.3 million, reflecting a growth of about 15% compared to the same period in 2024, despite falling short of expectations due to seasonal factors and the integration of new sales representatives [1][2][3]. Financial Performance - Expected total revenue for Q1 2025 is approximately $12.3 million, up from $10.8 million in Q1 2024, indicating a 15% increase [3]. - Q1 2024 revenue breakdown includes approximately $11.2 million from the U.S. and $1.1 million from Europe [3]. Sales and Market Strategy - The company is focused on enhancing Barostim adoption through a strengthened sales organization, having recruited new high-quality sales representatives [2]. - The first quarter of 2025 experienced seasonal softness, affecting revenue as patients scheduled procedures around insurance coverage and deductibles [2]. Operational Metrics - As of March 31, 2025, CVRx had 227 active implanting centers in the U.S., an increase from 223 as of December 31, 2024 [4]. - The number of sales territories in the U.S. decreased by 3 to a total of 45 during the first quarter of 2025 [4]. Cash Position - As of March 31, 2025, the company reported cash and cash equivalents of $102.7 million [4]. - During the first quarter, CVRx issued 543,462 shares of common stock for gross proceeds of $9.5 million under its at-the-market offering [4]. Upcoming Events - The company plans to release its full financial and operating results for Q1 2025 after market close on May 8, 2025, followed by a conference call at 4:30 p.m. Eastern Time [5][6].